Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. today... | June 14, 2023
United States Genevieve Neal Perry Naoki Okamura Astellas Pharma Prnewswire Astellas Pharma Inc Health Qual Life Outcomes
Source: marketscreener.com